| Abstrakt: |
The effect of triazolam on prior-sleep-mediated performance deficits (sleep inertia) was assessed. On Day I, subjects (45 healthy males, aged 18-39, tested in groups of two to four) reported to the laboratory at 0800h, at which time electrodes were attached for continuous ambulatory recordings of EEG, EMG, EOG. and EKG. Addition tests of 3mm duration were administered at 1400, 1405. 1410, 1415, 1420, and 1425h. After each test a Stanford Sleepiness Scale (SSS) was given to assess sell-rated sleepiness. Subjects were then kept awake until 0800 Ii on Day 2. when they were administered 05, 025, 0125mg triazolam or placebo. Subjects attempted to sleep from 0800 to 1400. at which time they were awakened (if asleep) and again administered the addition tests and SSSs, of 45 subjects, 24 were asleep during the 5 min period prior to testing, and only these were included in the analyses. A main effect of Day indicated decrements in addition speed on Day 2, f (1,20)=10.54,p=0.004, and a Day x Test interaction indicated sleep inertia effects, F(5, 100)=6.18, p=0.0001, Differential drug effects were indicated by a significant Day ` Drug interaction, F(3.20):3 19, p=0.046, and post-hoc analyses revealed that the number of problems attempted was significantly lower on Day 2 only for the 0.5 mg triazolam group. It was concluded that sleep inertia is exacerbated by 05 mg triazolam. [ABSTRACT FROM AUTHOR] |
